We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$37M
1-Year Est. Return
63.54%
This Fund
S&P 500
This Quarter
Est. Return
+8.57%
1 Year Est. Return
+63.54%
3 Year Est. Return
+38.32%
5 Year Est. Return
+47.02%
10 Year Est. Return
+2,091.28%
AUM
$562M
AUM Growth
+$310M
(+123%)
Cap. Flow
+$201M
Cap. Flow
% of AUM
35.7%
Top 10 Holdings %
Top 10 Hldgs %
34.85%
Holding
120
New
52
Increased
30
Reduced
2
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dentsply Sirona
XRAY
|
+$19M |
| 2 |
DexCom
DXCM
|
+$17M |
| 3 |
AGN
Allergan plc
AGN
|
+$16.3M |
| 4 |
Centene
CNC
|
+$13.8M |
| 5 |
Incyte
INCY
|
+$12.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$10M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$6.55M |
| 3 |
NXTM
NxStage Medical Inc.
NXTM
|
+$5.56M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$5.48M |
| 5 |
QGENF
QIAGEN NV
QGENF
|
+$5.26M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.64% |
| 2 | Miscellaneous | 25.71% |
| 3 | Industrials | 2.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$795B
| $25.1M | 4.47% |
+200,000
| New | +$49.3M |
|
2
Boston Scientific
BSX
$63.6B
| $22.8M | 4.05% |
780,000
+359,454
| +85% | +$9.93M |
|
3
LivaNova
LIVN
$4.33B
| $21.6M | 3.85% |
308,546
+168,544
| +120% | +$10.7M |
|
4
ICU Medical
ICUI
$3.89B
| $21.4M | 3.8% |
115,000
+70,000
| +156% | +$12.2M |
|
5
Merck
MRK
$358B
| $19.8M | 3.52% |
323,979
+187,739
| +138% | +$11.4M |
|
|
6
Dentsply Sirona
XRAY
$2.02B
| $19.1M | 3.41% |
+320,000
| New | +$19M |
|
7
CALL
Pfizer
PFE
$157B
| $17.9M | 3.18% |
+1,054,000
| New | +$33.9M |
|
8
Baxter International
BAX
$12.2B
| $16.9M | 3.02% |
270,000
+145,000
| +116% | +$8.96M |
|
|
IVC
9
DELISTED
Invacare Corporation
IVC
| $15.8M | 2.8% |
1,000,000
+495,000
| +98% | +$7.07M |
|
|
10
Centene
CNC
$32.6B
| $15.5M | 2.76% |
+320,000
| New | +$13.8M |
|
|
ATHN
11
DELISTED
Athenahealth, Inc.
ATHN
| $14.9M | 2.65% |
119,600
+76,600
| +178% | +$10.5M |
|
|
AGN
12
DELISTED
Allergan plc
AGN
| $14.3M | 2.55% |
+70,000
| New | +$16.3M |
|
|
ESRX
13
DELISTED
Express Scripts Holding Company
ESRX
| $12.7M | 2.25% |
200,000
+25,300
| +14% | +$1.57M |
|
|
XENT
14
DELISTED
Intersect ENT, Inc
XENT
| $12.5M | 2.22% |
400,000
+202,502
| +103% | +$5.99M |
|
15
Bio-Rad Laboratories Class A
BIO
$10.1B
| $12.4M | 2.21% |
56,000
+33,180
| +145% | +$7.47M |
|
|
16
DexCom
DXCM
$33B
| $11.7M | 2.09% |
+960,000
| New | +$17M |
|
|
17
Incyte
INCY
$25.3B
| $11.7M | 2.08% |
+100,000
| New | +$12.7M |
|
|
EVHC
18
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $11.1M | 1.97% |
246,384
+59,184
| +32% | +$3.16M |
|
19
Penumbra
PEN
$12.5B
| $10.8M | 1.92% |
119,158
+69,158
| +138% | +$5.96M |
|
20
QuidelOrtho
QDEL
$739M
| $9.65M | 1.72% |
+220,000
| New | +$7.66M |
|
21
Vertex Pharmaceuticals
VRTX
$130B
| $9.09M | 1.62% |
+59,800
| New | +$9M |
|
|
NSTG
22
DELISTED
NanoString Technologies, Inc.
NSTG
| $8.89M | 1.58% |
550,000
+151,794
| +38% | +$2.34M |
|
23
Axogen
AXGN
$2.67B
| $8.87M | 1.58% |
458,556
+279,187
| +156% | +$4.69M |
|
|
24
PUT
Baxter International
BAX
$12.2B
| $8.55M | 1.52% |
+270,000
| New | +$16.7M |
|
25
Abbott
ABT
$177B
| $8.54M | 1.52% |
+160,000
| New | +$8.03M |
|
Similar funds
MAM
GSEP
CTC
XA
YEPI
PEP
CP
WTG
Pura Vida Investments's Q3 2017 Portfolio in Review
As of Q3 2017, Pura Vida Investments held 120 positions worth $562M, up 123% from $252M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Pura Vida Investments deployed $201M of net new capital in Q3 2017, opening 52 new positions and adding to 30 existing holdings. Its largest new stake was Dentsply Sirona: 320,000 shares worth $19.1M.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 78% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $5.48M trimmed.
- Pura Vida Investments's largest Q3 2017 buy was Dentsply Sirona: 320,000 shares worth $19.1M.
- Pura Vida Investments added most to ICU Medical in Q3 2017, an estimated $12.2M increase.
- Pura Vida Investments's biggest Q3 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $5.48M.
- Pura Vida Investments fully exited Labcorp in Q3 2017, selling an estimated $10M.
- Pura Vida Investments's ten largest holdings make up 35% of its $562M portfolio in Q3 2017.
- Pura Vida Investments opened 52 new positions and closed 33 in Q3 2017.
- Pura Vida Investments's portfolio value rose 123% quarter-over-quarter to $562M.
Based on Pura Vida Investments's 13F filing for Q3 2017, filed 14 Nov 2017.